Evidence map›Paper›PMID 33257220›Full record

ReviewUrologic oncology2021

Bladder preservation: Translating discovery for clinical impact in urothelial cancer.

David T Miyamoto, Philip H Abbosh, Catharine M L West, Kent W Mouw

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Urologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

David T MiyamotoDepartment of Radiation Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Philip H AbboshMolecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA.
Catharine M L WestChristie NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
Kent W MouwDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: kent_mouw@dfci.harvard.edu.
Brigham and Women's Hospital · USFox Chase Cancer Center · USMassachusetts General Hospital · USUniversity of Manchester · GB

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Dietmar J Kappes · 1985 to 2026
$138.8M
Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancerK08CA219504 · NCI · DANA-FARBER CANCER INST · PI MOUW, KENT W · 2017 to 2021
$885k
NCI NIH HHS K08 CA219504NCI NIH HHS P30 CA006927
6 · The paper itself

Abstract

Muscle-invasive bladder cancer can be treated with either radical cystectomy or bladder preservation approaches, and there is a need for reliable biomarkers to guide the optimal choice of therapy. The recent elucidation of the genomic landscape and biological drivers of bladder cancer has enabled the identification of tumor molecular features that may be helpful in driving clinical decision-making. Here, we summarize recent efforts to develop molecular biomarkers that could be leveraged to guide therapeutic decisions, post-treatment monitoring, and the optimal use of bladder preservation approaches for the effective treatment of muscle-invasive bladder cancer.

Indexed as

Organ Sparing TreatmentsCarcinoma, Transitional CellHumansUrinary Bladder NeoplasmsBiomarkersBladder cancerBladder preservationTrimodality therapy

Identifiers

PMID33257220
PMCPMC9513532
OpenAlexW3109913105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.